Disease Spotlight: NMOSD

Specific Risk Factors Related to Permanent Disability in NMOSD Identified

October 25th 2022

Permanent disability, found in 51% of patients with NMOSD at follow-up, was attributed mainly to age of disease onset, delay in diagnosis, and initial EDSS score.

Similar Retinal Measurements Observed in Potential NMOSD and Definite NMOSD

October 18th 2022

A cross-sectional study showed that retinal measurements in patients with “potential” neuromyelitis optica spectrum disorder were similar to those with definite neuromyelitis optica spectrum disorder.

Anti-CD20 Therapies in Late-onset Neutropenia Result in an Uncommon Adverse Event

October 15th 2022

A report on two patients with late-onset neutropenia resulted in an uncommon adverse event following anti-CD20 therapies.

Greater Abnormal Visual Evoked Potential Found in NMOSD Than Idiopathic Demyelinating Optic Neuritis

October 15th 2022

P100 amplitude of 15 minute checks in the NMOSD-ON group had a significant reduction at 6 months relative to the IDON group, suggesting more several axonal damage.

Early Use of Immunosuppressives May Reduce Pregnancy-Related NMOSD Attacks

October 13th 2022

Annualized relapse rates were elevated compared with the prepregnancy period, especially during the initial 3 months after delivery, whereas EDSS scores worsened during pregnancy and the postpartum period.

Rituximab Treatment Associated with Reduced Relapse Rate in AQP4-IgG Positive NMOSD and MOGAD

October 11th 2022

A study using patient data from John Hopkins showed that rituximab treatment was associated with reduced annualized relapse rates in AQP4-IgG seropositive NMOSD and MOGAD.

Total N-Acetylaspartate Different Across Antibody-Negative Overlapping Multiple Sclerosis, NMOSD

October 8th 2022

Using magnetic resonance spectroscopy, investigators observed significantly different levels of total NAA across MS and NMOSD subtypes, and a negative correlation between total NAA and disability score.

Blocking B Cells may be the Key to Controlling NMOSD Over Time

September 15th 2022

Rituximab Displays Superiority to Azathioprine, Mycophenolate Mofetil as Initial NMOSD Treatment

September 13th 2022

Among a cohort of more than 300 patients in China, those with APQ4 positive NMOSD reported a significantly lower risk of relapse among those treated with rituximab compared with the other groups.

The Patient Perspective on Neuromyelitis Optica Spectrum Disorder: Sumaira Ahmed

September 8th 2022

The founder and executive director of the Sumaira Foundation offered her perspective on the patient journey in NMOSD and the vital need to increase awareness [WATCH TIME: 9 minutes]